MITOCONIX BIO

mitoconix-bio-logo

Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases. Mitochondria generates ATP, the energy source for all cellular activities. Mitochondria are also involved in other essential cellular functions, including calcium sequestration, amino acid and lipid metabolism, keeping balanced redox potential and orchestrating programmed cell death. In neurons in particular, mitochondria are very dynamic organelles that constan... tly undergo fission (division) and fusion. This process, called mitochondrial dynamics, is critical in maintaining healthy and functional mitochondria under both normal conditions and in response to stress and in ensuring having viable mitochondria along the axons and in the synaptic boutons. A defect in either fusion or fission limits mitochondrial motility, decreases energy production, increases oxidative stress and activates pro-apoptotic signaling thereby promoting cell dysfunction and death. Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).

#People #Financial #Website #More

MITOCONIX BIO

Industry:
Biotechnology Health Care Life Science

Founded:
2016-01-01

Address:
Jerusalem, Yerushalayim, Israel

Country:
Israel

Website Url:
http://www.mitoconix.com

Total Employee:
1+

Status:
Closed

Total Funding:
20 M USD

Technology used in webpage:
Domain Not Resolving Shutterstock


Current Employees Featured

eyal-neria_image

Eyal Neria
Eyal Neria CEO @ Mitoconix Bio
CEO

daria-mochly-rosen_image

Daria Mochly Rosen
Daria Mochly Rosen Founder @ Mitoconix Bio
Founder

Founder


daria-mochly-rosen_image

Daria Mochly Rosen

Investors List

rm-global-partners_image

RM Global Partners

RM Global Partners investment in Series A - Mitoconix Bio

arix-bioscience_image

Arix Bioscience

Arix Bioscience investment in Series A - Mitoconix Bio

dementia-discovery_image

Dementia Discovery Fund

Dementia Discovery Fund investment in Series A - Mitoconix Bio

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series A - Mitoconix Bio

remiges-ventures_image

Remiges Ventures

Remiges Ventures investment in Series A - Mitoconix Bio

Official Site Inspections

http://www.mitoconix.com

Unable to get host informations!!!

Loading ...

More informations about "Mitoconix Bio"

Mitoconix Bio - Crunchbase Company Profile & Funding

Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases. Mitochondria generates ATP, the energy source for all …See details»

Mitoconix Company Profile 2024: Valuation, Funding & Investors

Operator of a biopharmaceutical company intended to pioneer a novel strategy to improve mitochondrial health.See details»

Mitoconix Bio Ltd - VentureRadar

Mitoconix Bio is an emerging biopharmaceutical company developing disease modifying therapies addressing unmet medical need by improving mitochondrial health. Established in August …See details»

Mitoconix Bio Ltd. - Life-Sciences-Europe.com

Aug 1, 2016 · Mitoconix Bio Ltd is pioneering a novel strategy to improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases.See details»

Mitoconix Bio - Foreign Startup | Startup Nation Finder

Jun 27, 2017 · Mitoconix Bio is developing a strategy for improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases. The companys lead drug is an …See details»

Arix Bioscience participates in $20 million fundraise for

Jun 27, 2017 · Mitoconix Bio is pioneering a novel strategy to improve mitochondrial function as a disease-modifying therapeutic for treating neurodegenerative disorders, including …See details»

Mitoconix Bio - Funding, Financials, Valuation & Investors

Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases.See details»

Mitoconix Bio - Products, Competitors, Financials, Employees ...

Mitoconix Bio has developed a method of slowing neuro-degenerative diseases using drugs which improve mitochondrial functioning. Use the CB Insights Platform to explore Mitoconix Bio's full …See details»

Mitoconix Bio - Contacts, Employees, Board Members

Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases.See details»

Mitoconix Bio Ltd. - BioCentury Company Profiles - BCIQ

Mar 17, 2020 · Enter a Company name above to access free BCIQ profiles. Historical deals and financings can be found by searching the organization's name in the BCIQ Deals and …See details»

Mitoconix Bio Raises $20 Million in Series A Funding to Develop ...

Jun 27, 2017 · Mitoconix Bio Ltd., a biopharmaceutical company focused on therapies for neurological diseases, announced today that it has secured a $20 million round of Series A …See details»

Israeli startup takes aim at Huntington’s disease

Jul 5, 2017 · An Israeli biopharmaceutical company, Mitoconix Bio, has nabbed $20 million from investors to develop a promising drug for the treatment of Huntington’s disease and other …See details»

Mitoconix Bio Raises $20M in Series A Funding - FinSMEs

Jun 28, 2017 · Mitoconix Bio Ltd., a Ness Ziona, Israel-based biopharmaceutical company focused on therapies for neurological diseases, secured a $20m round of Series A funding. …See details»

Mitoconix Bio hits $20M series A for neurodegenerative R&D

Jun 27, 2017 · Preclinical startup Mitoconix Bio has secured a $20 million series A round for its research work on neurological disorders, including its lead candidate for Huntington’s disease.See details»

Mitoconix Bio Obtains $20 Million To Continue Developing …

Jun 29, 2017 · Mitoconix Bio has secured $20 million in financing to continue developing MTC-1203 as a treatment for mitochondrial impairment in Huntington’s and Parkinson’s diseases. …See details»

Mitoconix Bio Raises $20 Million In Series A Funding To ... - BioSpace

Jun 27, 2017 · Mitoconix Bio Ltd., a biopharmaceutical company focused on therapies for neurological diseases, announced today that it has secured a $20 million round of Series A …See details»

Israel's Mitoconix Bio raises $20 million in private funding round

Jun 27, 2017 · JERUSALEM (Reuters) - Mitoconix Bio, an Israeli biopharmaceutical company focused on treating neurological diseases, said on Tuesday it raised $20 million in an early …See details»

Mitoconix Bio - Longevity List

Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases. Mitochondria generates ATP, the energy source for all …See details»

MTC 1203 - AdisInsight

If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to …See details»

MFN2 agonists reverse mitochondrial defects in ... - Science | AAAS

Apr 20, 2018 · Mitofusins (MFNs) promote fusion-mediated mitochondrial content exchange and subcellular trafficking. Mutations in Mfn2 cause neurodegenerative Charcot-Marie-Tooth …See details»

linkstock.net © 2022. All rights reserved